Atlas Trials

To Evaluate Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Severe Renal Impairment Compared to Participants With Normal Renal Function

Clinical trial NCT05404542 · COMPLETED

Trial details

NCT number
NCT05404542
Sponsor
Cerevel Therapeutics, LLC
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Renal Impairment
Start date
2022-05-10
Primary completion
2023-08-14
Enrollment
14

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.